Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04568226
Other study ID # UW19-183
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 21, 2021
Est. completion date February 3, 2024

Study information

Verified date June 2024
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly diagnosed with curable cancer. This study aims to (1) test the direct effect of ConquerFear intervention on fear of cancer recurrence and on maladaptive metacognition, and (2) to test the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.


Description:

A randomized controlled trial will be conducted to test the effect of a metacognition-based manualized intervention on fear of cancer recurrence among Chinese breast, gynecologic and colorectal cancer patients with high levels of fear of cancer recurrence. The aims are to test: 1. the direct effect of ConquerFear intervention on fear of cancer recurrence, 2. the direct effect of ConquerFear intervention on maladaptive metacognition 3. the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition. Primary hypothesis: 1. Participants in the ConquerFear intervention will show a greater reduction in fear of cancer recurrence compared to participants in the control group 2. Participants in the ConquerFear intervention will show a greater reduction in maladaptive metacognition than the control participants 3. There will be an indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.


Recruitment information / eligibility

Status Completed
Enrollment 177
Est. completion date February 3, 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with non-metastatic breast cancer, gynecologic cancer, or colorectal cancer 2. had surgery as a primary treatment 3. have had completed hospital-based adjuvant treatments including radiotherapy and chemotherapy within the past 18 months 4. with the cut-off scored = 13 on Severity, the subscale of Fear of cancer inventory 5. are able to read and write Chinese 6. are over the age of 18 years Exclusion Criteria: 1. non-Chinese ethnicity 2. Patients diagnosed with metastatic cancer 3. with a current diagnosis of depression or psychosis 4. currently receiving psychological treatment 5. with language difficulties or intellectual disability.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ConquerFear Intervention
ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
Active control: Basic Cancer Care
Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.

Locations

Country Name City State
Hong Kong Kwong Wah Hospital-Breast Center Hong Kong
Hong Kong Prince of Wales Hospital-Department of Surgery Hong Kong
Hong Kong Queen Mary Hospital-Department of Obstetrics & Gynaecology Hong Kong
Hong Kong Queen Mary Hospital-Department of Surgery Hong Kong
Hong Kong The University of Hong Kong Jockey Club Institute of Cancer Care Hong Kong
Hong Kong Tung Wah Hospital-Department of Surgery Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong Research Grants Council, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

References & Publications (3)

Butow PN, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, Tesson S, O'Connell R, Girgis A, Gebski VJ, Asher R, Mihalopoulos C, Bell ML, Zola KG, Beith J, Thewes B. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. J Clin Oncol. 2017 Dec 20;35(36):4066-4077. doi: 10.1200/JCO.2017.73.1257. Epub 2017 Nov 2. — View Citation

Ng DWL, Foo CC, Ng SSM, Kwong A, Suen D, Chan M, Or A, Chun OK, Fielding BFS, Lam WWT. The role of metacognition and its indirect effect through cognitive attentional syndrome on fear of cancer recurrence trajectories: A longitudinal study. Psychooncology. 2020 Feb;29(2):271-279. doi: 10.1002/pon.5234. Epub 2019 Dec 23. — View Citation

Ng DWL, Kwong A, Suen D, Chan M, Or A, Ng SS, Foo CC, Fielding BFS, Lam WWT. Fear of cancer recurrence among Chinese cancer survivors: Prevalence and associations with metacognition and neuroticism. Psychooncology. 2019 Jun;28(6):1243-1251. doi: 10.1002/pon.5073. Epub 2019 Apr 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Demographic data Demographic data including age, gender, marital status, education level, occupation and monthly family income will be assessed by self-reported questionnaire Baseline
Other Clinical data Clinical data will be extracted from medical records. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Primary Fear of cancer recurrence The 42-items Fear of cancer recurrence inventory comprised of seven subscales will be used to assess the change of fear of cancer recurrence (FCR). Each item is rated on a 5-point Likert Scale with a total score ranging from 0 to 168. Higher scores indicate greater FCR. The subscale, Severity will be used as a screening tool for high level of FCR. A score of 13 or higher was optimal for screening. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Metacognitions The 30-items Metacognitions questionnaire (MCQ-30) will be used to assess the change of metacognitive beliefs.Each item is rated on a 4-point Likert scale with a total score ranging from 30 to 120. High scores indicate a more maladaptive metacognitive style. Baseline, immediate post-intervention, 3months post-intervention, and 6months
Secondary EORTC QLQ-C30 Quality of life (QoL) will be assessed by the EORTC QLQ-C30, in which incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Self-efficacy Self-efficacy for managing chronic disease will be assessed using the Self-Efficacy for Managing Chronic Disease 6-item Scale. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Coping behavior Coping behavior will be assessed using the 28-item Chinese Brief COPE. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Experimental avoidance Experimental avoidance will be assessed using the Acceptance and action questionnaire. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Cognitive Attentional Syndrome Cognitive Attentional Syndrome (CAS) will be assessed using the Cognitive-attentional Syndrome questionnaire (CAS-1). Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Intolerance of uncertainty Intolerance of uncertainty (IU) will be assessed using the 12-item Intolerance of uncertainty-12. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Psychological distress Psychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item measure of anxiety and depression widely used to assess cancer-related distress. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Cancer-related distress The 22-item Chinese Impact of Events Scale-revised (CIES-R) will be used to assess cancer-related distress, which comprised three subscales: avoidance, intrusive thoughts and hyperarousal symptoms measured using 5-point Likert scales. Higher mean scores on each subscale indicate greater avoidance/intrusiveness/arousal. Baseline, immediate post-intervention, 3months post-intervention, and 6months post-intervention
Secondary Treatment expectancy Treatment expectancy will be assessed using the 6-item credibility/ expectancy questionnaire. Baseline and immediate post-intervention
Secondary Therapeutic alliance The 12-item Working Alliance Inventory (WAI-SF)will be used to assess agreement on the therapy goal, patients' agreement with the therapist, and quality of the interpersonal bond. Both the participants and therapists will be asked to fill in the WAI-SF immediate post-intervention Immediate post-intervention
Secondary Treatment satisfaction Treatment satisfaction will be assessed using the evaluation form. Participants will be asked to indicate their overall satisfaction with the intervention they have received. Immediate post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05765916 - An Online Psychosocial Intervention for Fear of Cancer Recurrence in Breast Cancer Survivors N/A
Recruiting NCT04965428 - Fear-focused Self-Compassion Therapy for Young Breast Cancer Patients' Fear of Cancer Recurrence N/A
Not yet recruiting NCT06181344 - Implementation and Evaluation of a Fear of Cancer Recurrence Screening, Referral and Management Program N/A
Completed NCT04137575 - ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence N/A
Completed NCT04535921 - Fear of Cancer Recurrence in Genitourinary Cancer
Recruiting NCT06207006 - E-intervention on Subclinical Fear of Cancer Recurrence N/A
Not yet recruiting NCT06175208 - Targeting Fear of Cancer Recurrence in Cancer Survivors: Evaluation of Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as Intervention Strategies N/A
Active, not recruiting NCT04287218 - Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors N/A
Not yet recruiting NCT06181331 - The Effect of a Stepped-care Metacognition-based Intervention on Managing Fear of Cancer Recurrence N/A